Elanco Animal Health Inc (ELAN) concluded trading on Wednesday at a closing price of $13.33, with 6.94 million shares of worth about $92.51 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 10.17% during that period and on June 18, 2025 the price saw a loss of about -2.06%. Currently the company’s common shares owned by public are about 496.46M shares, out of which, 491.95M shares are available for trading.
Stock saw a price change of -6.59% in past 5 days and over the past one month there was a price change of 0.83%. Year-to-date (YTD), ELAN shares are showing a performance of 10.07% which decreased to -26.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.02 but also hit the highest price of $18.55 during that period. The average intraday trading volume for Elanco Animal Health Inc shares is 5.96 million. The stock is currently trading -1.46% below its 20-day simple moving average (SMA20), while that difference is up 15.16% for SMA50 and it goes to 8.82% higher than SMA200.
Elanco Animal Health Inc (NYSE: ELAN) currently have 496.46M outstanding shares and institutions hold larger chunk of about 100.91% of that.
The stock has a current market capitalization of $6.62B and its 3Y-monthly beta is at 1.68. PE ratio of stock for trailing 12 months is 17.79, while it has posted earnings per share of $0.75 in the same period. Its PEG reads 2.95 and has Quick Ratio of 1.46 while making debt-to-equity ratio of 0.69. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ELAN, volatility over the week remained 1.90% while standing at 1.96% over the month.
Stock’s fiscal year EPS is expected to drop by -7.67% while it is estimated to increase by 13.22% in next year. EPS is likely to shrink at an annualized rate of 6.04% for next 5-years, compared to annual growth of 29.95% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on December 09, 2024 offering a Buy rating for the stock and assigned a target price of $18 to it. Coverage by Leerink Partners stated Elanco Animal Health Inc (ELAN) stock as a Market perform in their note to investors on December 02, 2024, suggesting a price target of $14 for the stock. On September 19, 2024, Morgan Stanley Downgrade their recommendations, while on January 05, 2024, Stifel Upgrade their ratings for the stock with a price target of $20. Stock get a Buy rating from Jefferies on December 19, 2023.
